Moreover, CTD represses hepatic fibrosis through the WW domain-containing protein-2-mediated Notch3 degradation and enhances the sensitivity of doxorubicin treatment to chronic myeloid leukemia cells through the PI3K/AKT pathway [40,41]. Here, NOTCH3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.